Developments in oral enterotoxigenic Escherichia coli vaccines.
Journal
Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
03
02
2023
revised:
11
06
2023
accepted:
04
07
2023
medline:
23
10
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea in children in developing countries and in travelers. WHO has affirmed ETEC as a priority vaccine target, but there is no licensed ETEC vaccine available yet. We here describe recent, promising developments of different live, inactivated, and subunit ETEC candidate vaccines expressing or containing nontoxic enterotoxin and/or colonization factor antigens with a focus on oral vaccines. Many of the ETEC candidate vaccines have been tested in clinical trials for safety and immunogenicity and some of them also for protective efficacy in field trials or in challenge studies.
Identifiants
pubmed: 37523966
pii: S0952-7915(23)00091-2
doi: 10.1016/j.coi.2023.102372
pii:
doi:
Substances chimiques
Escherichia coli Vaccines
0
Vaccines, Subunit
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102372Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: A.M. S. is a shareholder of the biotech company Gotovax AB that may receive a small royalty on sales of ETVAX if it becomes a commercial product.